Acute graft rejection incidence

Method

Proportion of transplant recipients with at least one biopsy-proven or clinically treated acute rejection episode within the stated post-transplant window, usually twelve months, pooled as a risk ratio. Whether episodes were biopsy-confirmed or treated empirically is recorded on the edge.

The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.

Notes

SIGN INVERSION against one-year graft survival rate, which is reported in the same papers and often the same table. Both are proportions of the same transplant cohort, but rejection improves by FALLING and graft survival improves by RISING. They are also not complements - most acute rejection episodes are reversed and the graft survives - so neither can be recomputed from the other. Excludes chronic allograft nephropathy, and excludes calcineurin-inhibitor nephrotoxicity, which is a drug toxicity rather than an immune event and has its own node.